NEUROCRINE BIOSCIENCES INC (1NBIX.MI) Stock Price & Overview

BIT:1NBIXUS64125C1099

Current stock price

113 EUR
+1.45 (+1.3%)
Last:

The current stock price of 1NBIX.MI is 113 EUR. Today 1NBIX.MI is up by 1.3%.

1NBIX.MI Key Statistics

Market Cap
11.341B
P/E
28.39
Fwd P/E
21.37
EPS (TTM)
3.98
Dividend Yield
N/A

1NBIX.MI Stock Performance

Today
+1.3%
1 Week
-5.87%
1 Month
N/A
3 Months
N/A
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

1NBIX.MI Stock Chart

NEUROCRINE BIOSCIENCES INC / 1NBIX Daily stock chart

1NBIX.MI Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to 1NBIX.MI.


Chartmill TA Rating
Chartmill Setup Rating

1NBIX.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to 1NBIX.MI. 1NBIX.MI has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

1NBIX.MI Earnings

On February 11, 2026 1NBIX.MI reported an EPS of 1.48 and a revenue of 805.50M. The company missed EPS expectations (-22.89% surprise) and missed revenue expectations (-0.28% surprise).

Next Earnings DateMay 6, 2026
Last Earnings DateFeb 11, 2026
PeriodQ4 / 2025
EPS Reported$1.48
Revenue Reported805.5M
EPS Surprise -22.89%
Revenue Surprise -0.28%

1NBIX.MI Forecast & Estimates

36 analysts have analysed 1NBIX.MI and the average price target is 152.97 EUR. This implies a price increase of 35.38% is expected in the next year compared to the current price of 113.

For the next year, analysts expect an EPS growth of 32.86% and a revenue growth 21.05% for 1NBIX.MI


Analysts
Analysts84.44
Price Target152.97 (35.37%)
EPS Next Y32.86%
Revenue Next Year21.05%

1NBIX.MI Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

1NBIX.MI Financial Highlights

Over the last trailing twelve months 1NBIX.MI reported a non-GAAP Earnings per Share(EPS) of 3.98. The EPS increased by 41.64% compared to the year before.


Income Statements
Revenue(TTM)2.86B
Net Income(TTM)478.60M
Industry RankSector Rank
PM (TTM) 16.73%
ROA 10.33%
ROE 14.71%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%48%
Sales Q2Q%28.33%
EPS 1Y (TTM)41.64%
Revenue 1Y (TTM)21.45%

1NBIX.MI Ownership

Ownership
Inst Owners100.45%
Shares100.36M
Float98.55M
Ins Owners1.11%
Short Float %N/A
Short RatioN/A

About 1NBIX.MI

Company Profile

1NBIX logo image Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 2,000 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Company Info

IPO: 1996-05-23

NEUROCRINE BIOSCIENCES INC

6027 Edgewood Bend Court

San Diego CALIFORNIA US

Employees: 2000

1NBIX Company Website

1NBIX Investor Relations

Phone: 18586177600

NEUROCRINE BIOSCIENCES INC / 1NBIX.MI FAQ

Can you describe the business of NEUROCRINE BIOSCIENCES INC?

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 2,000 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.


What is the current price of 1NBIX stock?

The current stock price of 1NBIX.MI is 113 EUR. The price increased by 1.3% in the last trading session.


What is the dividend status of NEUROCRINE BIOSCIENCES INC?

1NBIX.MI does not pay a dividend.


What is the ChartMill technical and fundamental rating of 1NBIX stock?

1NBIX.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 7 out of 10.


Where is NEUROCRINE BIOSCIENCES INC (1NBIX.MI) stock traded?

1NBIX.MI stock is listed on the Euronext Milan exchange.


Can you provide the sector and industry classification for NEUROCRINE BIOSCIENCES INC?

NEUROCRINE BIOSCIENCES INC (1NBIX.MI) operates in the Health Care sector and the Biotechnology industry.